Search

Your search keyword '"Motwani M"' showing total 386 results

Search Constraints

Start Over You searched for: Author "Motwani M" Remove constraint Author: "Motwani M"
386 results on '"Motwani M"'

Search Results

1. The Importance of HOA Reduction Measurements to Improving Refractive Surgery Result Outcomes [Letter]

2. A Novel Procedure for Keratoconus/Corneal Ectasia Treating Epithelial Compensation of Higher-Order Aberrations, Topographic Guided Ablation, and Corneal Cross Linking – The CREATE+CXL Protocol

4. Treatment of Corneal Irregularity in Radial/Astigmatic Keratotomy Patients Utilizing WaveLight Contoura

5. Treatment of Keratoconus with WaveLight Contoura and Corneal Cross-Linking Combined

6. Analysis and Causation of All Inaccurate Outcomes After WaveLight Contoura LASIK with LYRA Protocol

7. Predictions of Residual Astigmatism from Surgical Planning for Topographic-Guided LASIK Based on Anterior Corneal Astigmatism (LYRA Protocol) vs the Phorcides Analytic Engine

8. Biomechanical Changes to the Cornea from LASIK Flap Creation Resulting in Inaccurate Ablations and Suboptimal Refractive Outcomes with Topographic-Guided Ablation

9. Clinical Outcomes After Topography-guided Refractive Surgery in Eyes with Myopia and Astigmatism—Comparing Results with New Planning Software to Those Obtained Using the Manifest Refraction [Letter]

10. Response to the Correct Usage of the Term “off-Label” in the Context of Corneal Cross-Linking [Response To Letter]

11. Response to: WaveLight® Contoura topography-guided planning: contribution of anterior corneal higher-order aberrations and posterior corneal astigmatism to manifest refractive astigmatism

12. The use of WaveLight Contoura to create a uniform cornea: 6-month results with subjective patient surveys

13. Topographic-guided treatment of hyperopic corrections with a combination of higher order aberration removal with WaveLight® Contoura and wavefront-optimized hyperopic treatment

14. Treatment of high myopia/myopic astigmatism with a combination of WaveLight Contoura with LYRA protocol and wavefront-optimized treatment

15. Treatment of moderate-to-high hyperopia with the WaveLight Allegretto 400 and EX500 excimer laser systems

16. The use of WaveLight® Contoura to create a uniform cornea: the LYRA Protocol. Part 2: the consequences of treating astigmatism on an incorrect axis via excimer laser

17. The use of Wavelight® Contoura to create a uniform cornea: the LYRA protocol. Part 3: the results of 50 treated eyes

18. The use of Wavelight® Contoura to create a uniform cornea: the LYRA Protocol. Part 1: the effect of higher-order corneal aberrations on refractive astigmatism

19. A protocol for topographic-guided corneal repair utilizing the US Food and Drug Administration-approved Wavelight Contoura

20. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19

22. 214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study

23. 30-day morbidity and mortality of sleeve gastrectomy, Roux-en-Y gastric bypass and one anastomosis gastric bypass: a propensity score-matched analysis of the GENEVA data

24. List of Contributors

27. MO31-2 Telisotuzumab vedotin monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer

31. 30-Day morbidity and mortality of bariatric metabolic surgery in adolescence during the COVID-19 pandemic – The GENEVA study

32. Contributors

34. Machine learning from quantitative coronary computed tomography angiography predicts ischemia and impaired myocardial blood flow

36. P47.03 Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2

37. Machine Learning From Quantitative Coronary Computed Tomography Angiography Predicts Ischemia And Impaired Myocardial Blood Flow

38. 30-day morbidity and mortality of sleeve gastrectomy, Roux-en-Y gastric bypass and one anastomosis gastric bypass: a propensity score-matched analysis of the GENEVA data

44. MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer

48. An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

Catalog

Books, media, physical & digital resources